Liam Griffiths is a researcher and former PhD student associated with the School of Biomedical Sciences and the Frazer Institute at The University of Queensland. His work has focused on cancer research and antibody-dependent cell cytotoxicity (ADCC), specifically investigating melanoma heterogeneity and trastuzumab-induced cardiotoxicity.

Dr. Canan Nebigil-Désaubry’s research program addresses fundamental and translational questions in cardiovascular biology by elucidating how G protein-coupled receptors (GPCRs) orchestrate heart development, cardiometabolic homeostasis, and disease. She has established a distinctive research line focused on serotonin and prokineticin signaling, positioning GPCRs as actionable therapeutic targets in cardiovascular and metabolic disorders. After completing her Pharm.D. and Ph.D. at the University of Tennessee, she trained with Robert Lefkowitz at Duke University, gaining advanced expertise in GPCR biology. She then served as a Senior Scientist at the NIH and IGBMC, France, before establishing her independent group at ESBS, CNRS Unite via a highly competitive ATIP-Avenir award. Currently, she is Research Director at CNRS and a member of the Laboratory of Excellence. Her team discovered the roles of serotonin 5-HT2B receptor and prokineticins in cardiac physiology and metabolism, identified the first non-peptide PKR1 agonist, and developed innovative cardiac organoid–tumor co-culture platforms to advance translational cardio-oncology research.

Ce Cao is a Ph.D. candidate at the China Academy of Chinese Medical Sciences, currently undertaking a state-sponsored joint training program at the National University of Singapore. His research focuses on cardiovascular pharmacology, specifically cardiac repair and regeneration post-myocardial infarction, and the pharmacological mechanisms of active components in Traditional Chinese Medicine. He has published multiple peer-reviewed papers as a first or co-first author and co-invented several patents related to cardiomyocyte repair therapies. He also serves as a youth committee member of the Network Pharmacology Professional Committee of the Chinese Pharmacological Society.

Dr Miles De Blasio is head of the Cardio-Metabolic Physiology laboratory and also co-lab head of the Heart Failure Pharmacology laboratory at Monash Institute of Pharmaceutical Sciences, Monash University. His current research focus is on the cardiometabolic alterations that occur in the heart in response to obesity-related diseases and the metabolic changes that occur in animal models of diabetes, cardiometabolic HFpEF and obesity. He has authored 85 publications in journals such as Nature Reviews Cardiology, Trends in Pharmacological Sciences, British Journal of Pharmacology, Cardiovascular Research, and Cardiovascular Diabetology. He is an Invited Associate Editor for Cardiovascular Diabetology, a member of Victorian Cardiovascular Research Network (VCRN), the Victorian Heart Institute (VHI), the International Society of Heart Research (ISHR), & the Cardiac Society of Australia and New Zealand (CSANZ).

Dr. Wai San Cheang is currently the Associate Professor and serves as Assistant Director (Global Affairs) of the Institute of Chinese Medical Sciences, State Key Laboratory of Mechanism and Quality of Chinese Medicine, at University of Macau. She received her PhD degree in Physiology from the Chinese University of Hong Kong in 2014. She received the postdoctoral training at the Chinese University of Hong Kong and University of California, San Diego. Her research interest is vascular and metabolic biology, identifying novel biomarkers/ therapeutic targets in vascular and metabolic dysfunction and pharmacological characterization of Chinese medicine in vasculature. She has published 90 articles on peer-reviewed journals (h-index of 36). She is the Council Member of The Chinese Society of Cardiovascular Pharmacology, Chinese Pharmacological Society (2021-), Macau Pharmacology Association (2022-), and Macau Association for Young Scientists (2023-).